| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528109 | Clinical Therapeutics | 2018 | 15 Pages |
Abstract
Bioequivalence of dapagliflozin/metformin XR FCDP and the individual components was established without any new safety concerns, presenting a safe alternative for patients currently receiving regimens including each component individually. ClinicalTrials.gov identifier: NCT02722239.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Yunona PhD, MD, Nadezhda MPharm, Konstantin MD, Svetlana PhD, MD, Victoria PhD, Brian PhD, PMP, Nigel PhD, David W. PhD, Weifeng PhD, MD,